Pharmaceutical composition for treating hypertension and cardiovascular disease

A composition and cardiovascular technology, applied in the field of medicine, can solve the problems of not taking into account the regularity of blood pressure changes in patients, low blood pressure, and unsatisfactory blood pressure control, and achieve the effects of eliminating adverse reactions, reducing blood volume, and avoiding photolysis.

Inactive Publication Date: 2006-12-27
CSPC OUYI PHARM CO LTD
View PDF3 Cites 40 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented new type of tablet described in this patents allows for easier swallowing without causing disorders like heartburn due to increased absorption caused by certain substances found naturally occurring during manufacturing processes. It achieves these benefits through enhancing the release properties of various types of drugs from their delivery system.

Problems solved by technology

Technologies aimed towards developing better medications target specifically against cardiogenic vasculature related conditions such ashypertension caused by increased levels of circulating calcium overload due to abnormalities in renal function. However, current methods require multiple dosings perday while being time-consuming and potentially causing harmful side effects when taken frequently throughout the entire body. Therefore there needs a more efficient and reliable way to administer these agents without compromising their efficacy during peak hours.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating hypertension and cardiovascular disease
  • Pharmaceutical composition for treating hypertension and cardiovascular disease
  • Pharmaceutical composition for treating hypertension and cardiovascular disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-13

[0022] The dosage forms of the pharmaceutical compositions of Examples 1 to 13 are tablets, and the raw material formulations of each example are the amount for preparing 1000 tablets, and the unit is gram. The raw material formula of embodiment 1 to embodiment 13 is provided by table 1.

[0023] The preparation method of Example 1 to Example 13: Grinding levamlodipine salt, angiotensin II receptor antagonist, corresponding cyclodextrin and water efficiently and quickly for 1 hour, then drying in vacuum at 40°C, pulverizing, passing through 1000 Mesh sieve, then add the remaining materials, mix in a mixer for 10 minutes, press into tablets, and pack after passing the test.

[0024] Usage: take orally, once a day, one tablet each time, take it in the morning.

Embodiment 14-16

[0026] The dosage forms of the pharmaceutical compositions of Examples 14 to 16 are capsules, and the raw material formulations of each example are the amount of medicine in 1000 capsules, and the unit is gram. The raw material formula of embodiment 14 to embodiment 16 is provided by table 2.

[0027] The preparation method of Example 14 to Example 16: Preparation method: Grind levamlodipine salt, angiotensin II receptor antagonist, cyclodextrin and water efficiently and rapidly for 1 hour, then dry in vacuum at 40° C., pulverize, pass 1000-mesh sieve, then add the remaining materials, mix in a mixer for 10 minutes, pack into capsules, and pack after passing the test.

[0028] Usage: Orally, once a day, one tablet each time, in the morning.

Embodiment 17-19

[0030]The dosage forms of the pharmaceutical compositions of Examples 17 to 19 are injections, and the raw material formulations of each example are the amount for preparing 100 injections, and the unit is gram. The raw material formula of embodiment 17 to embodiment 19 is provided by table 3.

[0031] The preparation method of Example 17 to Example 19: Dissolve sodium chloride in water for injection, add levamlodipine salt, angiotensin II receptor antagonist, further add water for injection after dissolving, adjust the volume to the required concentration , and then the solution is subjected to sterile filtration, and filled into ampoules or oral liquid bottles under aseptic conditions.

[0032] How to use: Inject, once a day, one each time, use in the morning.

[0033] Table 1 Unit: Gram

[0034]

[0035] Table 2 Unit: Gram

[0036]

[0037] Table 3 Unit: Gram

[0038]

[0039] Medicine of the present invention has been tested, and 200 routine hypertensive patie...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating hypertension and other cardiovascular diseases, wherein the active constituents include pharmaceutical salts of levamlodipine besylate and angiotensin II receptor antagonists. The invention can not only overcome the drawback of photodecomposition of the levoamlodipine maleate medicaments, but also can increase the dissolving degree by 21%.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner CSPC OUYI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap